Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)

R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen ClackAshwani Bahl, Stuart McIntosh, Matthew G. Krebs

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row originally read “Liver metastases (N = 14); 2.8 (1.8, 5.3)” The change is reflected in the HTML and PDF versions of the article.

Original languageEnglish
Article number2242
JournalNature Communications
Volume16
Issue number1
DOIs
StatePublished - Dec 2025

Fingerprint

Dive into the research topics of 'Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)'. Together they form a unique fingerprint.

Cite this